Takasaki K, et al. - Bevacizumab and gemcitabine (Bev–Gem) vs gemcitabine (Gem) only were compared as treatment options for patients with platinum-resistant recurrent ovarian cancer (PROC). Findings suggested Bev–Gem could be a candidate treatment strategy for PROC as Bev–Gem regimens improved progression-free survival and overall survival and had tolerable adverse effects in patients with PROC.